Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
BLESS fluctuates 145.5% in 24 hours: Abnormal trading volume and on-chain activity drive speculative pump

BLESS fluctuates 145.5% in 24 hours: Abnormal trading volume and on-chain activity drive speculative pump

Bitget PulseBitget Pulse2026/04/14 22:03
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, BLESS price rebounded from a low of $0.0152 to a high of $0.0373, currently quoted at $0.0185, with a price fluctuation reaching 145.5%. Trading volume surged to $128 million, the market cap is approximately $35.7 million, and liquidity has improved significantly.

Brief Analysis of the Abnormal Movement

- Unusually high trading volume: 24-hour volume soared over 140% to exceed $100 million, driving the price to rally rapidly from a $0.0128 low, indicating strong speculative buying.

- Active on-chain activity signals: Monitoring shows abnormal increases in on-chain transactions, supporting the price pump, but concerns about liquidity remain.

- Exchange listing: WEEX added the BLESS/USDT trading pair on April 14, 2026, improving accessibility.

Market Opinions & Outlook

Mainstream sentiment in the community is bullish, with traders on X viewing this as a strong pump and expecting another rally after a pullback (targeting $0.022-$0.026). However, there are widespread warnings of FOMO risks and potential liquidity sweep traps, suggesting to wait for $0.0176 support confirmation before entering. If trading volume falls below $15 million, the outlook may turn weak.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for information reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

From Lowering Blood Sugar and Weight Loss to Cardiovascular Protection! Mounjaro Achieves "Cardiometabolic Leap," Lilly (LLY.US) Opens GLP-1's Second Growth Curve

Eli Lilly's diabetes drug Mounjaro has received approval in the United States for reducing the risk of serious cardiovascular disease. The U.S. Food and Drug Administration has approved Mounjaro for lowering cardiovascular risk in adults with type 2 diabetes who have established heart disease.

智通财经2026/08/28 12:36
From Lowering Blood Sugar and Weight Loss to Cardiovascular Protection! Mounjaro Achieves "Cardiometabolic Leap," Lilly (LLY.US) Opens GLP-1's Second Growth Curve